You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Walnuts May Improve Lipid Profile in Type 2 Diabetes

  • Authors: News Author: Laurie Barclay, MD
    CME Author: Charles Vega, MD, FAAFP
  • CME Released: 12/1/2004; Reviewed and Renewed: 12/6/2005
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/6/2006
Start Activity


Target Audience and Goal Statement

This article is intended for primary care physicians, endocrinologists, cardiologists, and other specialists who care for patients with type 2 diabetes.

The goal of this activity is to provide the latest medical news to physicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  • Describe the metabolic effects of fish and nuts in the diet.
  • Identify outcomes improved through a modified low-fat diet that includes daily walnut intake.


Disclosures

As an organization accredited by the ACCME, Medscape requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as "financial relationships in any amount, occurring within the past 12 months, that create a conflict of interest."

Medscape encourages Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Laurie Barclay, MD

    Laurie Barclay is a freelance reviewer and writer for Medscape.

    Disclosures

    Disclosure: Dr. Barclay has reported no significant financial interests.

Reviewer(s)

  • Gary Vogin, MD

    Senior Medical Editor, Medscape

    Disclosures

    Disclosure: Dr. Vogin has reported no significant financial interests.

CME Author(s)

  • Charles P Vega, MD

    Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine

    Disclosures

    Disclosure: Dr. Vega has disclosed that he has received grants for educational activities from Pfizer.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape designates this educational activity for 0.25 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

Walnuts May Improve Lipid Profile in Type 2 Diabetes

Authors: News Author: Laurie Barclay, MD CME Author: Charles Vega, MD, FAAFPFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 12/1/2004; Reviewed and Renewed: 12/6/2005

Valid for credit through: 12/6/2006

processing....

Dec. 1, 2004 -- Adding walnuts to a low-fat diet improves lipid profile for patients with type 2 diabetes, according to the results of a randomized study published in the December issue of Diabetes Care.

"Walnuts are distinguished from other nuts by virtue of their higher polyunsaturated fat content (and importantly their α-linolenic acid [ALA] content) combined with antioxidants in the form of γ-tocopherol," write Linda C. Tapsell, PhD, from the National Centre of Excellence in Functional Foods, University of Wollongong in New South Wales, Australia, and colleagues. "There are mechanistic explanations for the influence of dietary polyunsaturated fatty acid (PUFA) on insulin action and energy metabolism, and cohort studies of women in the U.S. have demonstrated a reduced risk of developing type 2 diabetes with dietary PUFA replacing trans or saturated fatty acids (SFAs)."

In this parallel design trial, 58 adults with type 2 diabetes were randomized to one of three dietary advice groups, each with 30% energy as fat: low fat, modified low fat, and modified low fat inclusive of 30 g of walnuts per day. Mean age was 59.3 ± 8.1 years.

Patients received dietary advice at baseline, with monthly follow-up and telephone calls bimonthly for support. All groups were advised to consume fish and five daily portions of fruits and vegetables. Body weight, percent body fat, blood lipids, glycosylated hemoglobin (HbA 1c), total antioxidant capacity, and erythrocyte fatty acid levels were measured at baseline and at three and six months, and analysis was by intent-to-treat.

Erythrocyte biomarkers of dietary intake confirmed higher dietary polyunsaturated fat-to-saturated fat ratio and intakes of ω-3 fatty acids in the walnut group. Compared with the two other treatment groups, the walnut group had a significantly greater increase in high-density lipoprotein (HDL) cholesterol-to-total cholesterol ratio ( P = .049) and in HDL ( P = .046). The walnut group also had a 10% reduction in low-density lipoprotein (LDL) cholesterol, reflecting a significant effect by group ( P = .03) and time ( P = .04).

The three groups were similar in changes in body weight, percent body fat, total antioxidant capacity, and HbA 1c levels.

Study limitations include open recruitment; participation of only 50% of volunteers, limiting generalizability of the results; and lower baseline cholesterol levels in the walnut group.

"Structured 'whole of diet' advice that included 30 g of walnuts/day delivering substantial amounts of polyunsaturated fatty acid improved the lipid profile of patients with type 2 diabetes," the authors conclude.

The Australian Research Council and the California Walnut Commission funded this study.

Diabetes Care. 2004;27:2777-2783

  • Print